January 3, 2019 / 2:27 AM / 13 days ago

CORRECTED-BRIEF-Teva And Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalcet HCl Product

(Corrects spelling of drug in headline and first bullet)

Jan 2 (Reuters) - Teva Pharmaceutical Industries Ltd :

* TEVA AND AMGEN RESOLVE ONGOING DISPUTE OVER TEVA’S GENERIC CINACALCET HCL PRODUCT

* TEVA WILL PAY AMGEN AN UNDISCLOSED AMOUNT AS PART OF THE SETTLEMENT

* THE AMOUNT AND OTHER TERMS OF SETTLEMENT REMAIN CONFIDENTIAL

* TEVA PHARMACEUTICAL INDUSTRIES- LITIGATION BETWEEN PARTIES TO BE ENDED

* TEVA PHARMACEUTICAL INDUSTRIES- CO AGREED TO STOP SELLING ITS GENERIC PRODUCT UNTIL LICENSE DATE IN MID 2021, OR EARLIER UNDER CERTAIN CIRCUMSTANCES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below